Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume -, Issue -, Pages 1-15
Publisher
Informa UK Limited
Online
2021-03-06
DOI
10.1080/21645515.2020.1870846
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma
- (2020) Robert A. Figlin et al. CLINICAL CANCER RESEARCH
- Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
- (2020) Michael D. Crowther et al. NATURE IMMUNOLOGY
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
- (2020) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A.
- (2020) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
- (2020) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
- (2020) David A. Braun et al. NATURE MEDICINE
- Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
- (2020) Federica Cappuccini et al. Journal for ImmunoTherapy of Cancer
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
- (2020) Robert J. Motzer et al. NATURE MEDICINE
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Integrated epigenomic profiling reveals endogenous retrovirus reactivation in renal cell carcinoma
- (2019) Kyle T. Siebenthall et al. EBioMedicine
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
- (2019) Jean-Christophe Pignon et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma
- (2019) Pooja Ghatalia et al. Journal for ImmunoTherapy of Cancer
- T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes
- (2019) Tomasz Kula et al. CELL
- T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study
- (2019) Stacey L. Doran et al. JOURNAL OF CLINICAL ONCOLOGY
- CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models
- (2019) Huizhong Li et al. JOURNAL OF IMMUNOTHERAPY
- Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma
- (2019) Yuexin Xu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Simultaneous Deletion of Endogenous TCRαβ for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic
- (2019) Laura T. Morton et al. MOLECULAR THERAPY
- Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function
- (2019) Sharyn Thomas et al. Nature Communications
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma
- (2018) Guillermo de Velasco et al. BRITISH JOURNAL OF CANCER
- Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes
- (2018) Marvin H. Gee et al. CELL
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
- (2018) Masahiro Ogasawara et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma
- (2018) Christof C. Smith et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring
- (2017) Tanja Scheikl-Gatard et al. Journal of Translational Medicine
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Identification of essential genes for cancer immunotherapy
- (2017) Shashank J. Patel et al. NATURE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance
- (2017) Yinmeng Yang et al. Science Translational Medicine
- 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy
- (2017) Federica Cappuccini et al. Oncotarget
- Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients
- (2017) Chiara Massa et al. Oncotarget
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma
- (2016) Wataru Obara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer
- (2016) Peter L. Stern et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer
- (2016) Elena Cherkasova et al. CANCER RESEARCH
- Tim-3 Expression on Tumor-Infiltrating PD-1 + CD8 + T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma
- (2016) Clémence Granier et al. CANCER RESEARCH
- A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN versus IFN in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
- (2016) R. E. Hawkins et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Prognostic and Clinicopathological Significance of Survivin Expression in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
- (2016) Yongpeng Xie et al. Scientific Reports
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use
- (2015) Jaromir Pastorek et al. SEMINARS IN CANCER BIOLOGY
- Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
- (2015) Eyad Elkord et al. Oncotarget
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
- (2015) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- IMA901: A multi-peptide cancer vaccine for treatment of renal cell cancer
- (2015) Alexandra Kirner et al. Human Vaccines & Immunotherapeutics
- Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma
- (2014) Myoung Jae Kang et al. Translational Oncology
- Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
- (2013) K Yoshimura et al. BRITISH JOURNAL OF CANCER
- Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
- (2013) R. Remark et al. CLINICAL CANCER RESEARCH
- Transcriptional Profiling of Human Endogenous Retrovirus Group HERV-K(HML-2) Loci in Melanoma
- (2013) Katja Schmitt et al. Genome Biology and Evolution
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reviews Spontaneous regression of renal cell carcinoma
- (2013) Anna Daria Janiszewska et al. Wspolczesna Onkologia-Contemporary Oncology
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4
- (2013) Rabih Said et al. Frontiers in Oncology
- High DGK- and Disabled MAPK Pathways Cause Dysfunction of Human Tumor-Infiltrating CD8+ T Cells That Is Reversible by Pharmacologic Intervention
- (2012) P. U. Prinz et al. JOURNAL OF IMMUNOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge
- (2012) David Roulois et al. Biomed Research International
- Intratumoral alterations of dendritic-cell differentiation and CD8+T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma
- (2012) Elfriede Noessner et al. OncoImmunology
- Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
- (2011) Paul F. Robbins et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Inactivation of the von Hippel–Lindau tumor suppressor leads to selective expression of a human endogenous retrovirus in kidney cancer
- (2011) E Cherkasova et al. ONCOGENE
- A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
- (2010) Stéphane Oudard et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2010) R. J. Amato et al. CLINICAL CANCER RESEARCH
- Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity
- (2010) Göran Forsberg et al. JOURNAL OF IMMUNOTHERAPY
- A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma
- (2010) Osama E Rahma et al. Journal of Translational Medicine
- Development and evaluation of BioScore
- (2009) Alexander S. Parker et al. CANCER
- Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
- (2009) Robert E. Hawkins et al. JOURNAL OF IMMUNOTHERAPY
- Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α)
- (2009) Robert J. Amato et al. JOURNAL OF IMMUNOTHERAPY
- Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
- (2009) Howard L Kaufman et al. Journal of Translational Medicine
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005)
- (2008) Arie S. Belldegrun et al. CANCER
- Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
- (2008) R. J. Amato et al. CLINICAL CANCER RESEARCH
- Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4
- (2008) W. H. Shingler et al. INTERNATIONAL IMMUNOLOGY
- Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells
- (2008) Yoshiyuki Takahashi et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytokine Maturation Followed by CD40L mRNA Electroporation Results in a Clinically Relevant Dendritic Cell Product Capable of Inducing a Potent Proinflammatory CTL Response
- (2008) David M. Calderhead et al. JOURNAL OF IMMUNOTHERAPY
- An MVA-based Vaccine Targeting the Oncofetal Antigen 5T4 in Patients Undergoing Surgical Resection of Colorectal Cancer Liver Metastases
- (2008) Eyad Elkord et al. JOURNAL OF IMMUNOTHERAPY
- Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
- (2008) Annika Berntsen et al. JOURNAL OF IMMUNOTHERAPY
- Human Endogenous Retrovirus K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer
- (2008) R. Contreras-Galindo et al. JOURNAL OF VIROLOGY
- Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes
- (2008) Tanja Ninkovic et al. MOLECULAR IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started